Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer
Conclusions Lurbinectedin is highly effective on uterine cervical cancer because it eliminates CSCs, and lurbinectedin is a promising agent to overcome platinum resistance in cervical cancer.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Cervical Cancer | Drugs & Pharmacology | Genetics | Investigational New Drugs | Nanotechnology | Stem Cell Therapy | Stem Cells | Study